Haleon PLC Sponsored ADR $HLN Position Reduced by Cambiar Investors LLC

Cambiar Investors LLC reduced its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 94.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 66,003 shares of the company’s stock after selling 1,229,351 shares during the period. Cambiar Investors LLC’s holdings in Haleon were worth $592,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Golden State Wealth Management LLC grew its position in Haleon by 107.6% during the 2nd quarter. Golden State Wealth Management LLC now owns 2,721 shares of the company’s stock worth $28,000 after purchasing an additional 1,410 shares in the last quarter. SOA Wealth Advisors LLC. lifted its holdings in shares of Haleon by 60.5% in the third quarter. SOA Wealth Advisors LLC. now owns 3,105 shares of the company’s stock valued at $28,000 after purchasing an additional 1,170 shares in the last quarter. Citizens National Bank Trust Department boosted its position in shares of Haleon by 167.4% in the third quarter. Citizens National Bank Trust Department now owns 3,276 shares of the company’s stock worth $29,000 after buying an additional 2,051 shares during the period. Hilltop National Bank purchased a new position in shares of Haleon during the second quarter valued at $33,000. Finally, Pittenger & Anderson Inc. purchased a new position in shares of Haleon during the second quarter valued at $36,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Down 1.0%

Haleon stock opened at $10.32 on Thursday. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48. Haleon PLC Sponsored ADR has a 1-year low of $8.71 and a 1-year high of $11.42. The firm’s fifty day simple moving average is $9.90 and its 200-day simple moving average is $9.61. The company has a market capitalization of $45.94 billion, a P/E ratio of 26.45 and a beta of 0.19.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Morgan Stanley reissued an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. Jefferies Financial Group reissued a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft cut shares of Haleon from a “hold” rating to a “sell” rating in a report on Monday, January 12th. Hsbc Global Res upgraded shares of Haleon from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 21st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.33.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.